Brii Biosciences Limited (02137) published a Next Day Disclosure Return on October 27, 2025, reporting changes to its issued share capital. The opening balance of issued shares (excluding treasury shares) was 720,323,173 as of September 30, 2025, and the closing balance reached 720,776,548 as of October 27, 2025. Treasury shares remained at 12,723,500, resulting in a total of 733,500,048 shares.

Several instances of new share issuances and allotments occurred during the period, primarily tied to three share schemes: a pre-IPO share incentive plan adopted on October 30, 2018; a Post-IPO Share Award Scheme adopted on June 22, 2021; and a 2023 Share Award or Share Option Scheme adopted on September 1, 2023. The shares were issued at various prices, including USD0.035 and HKD0.964, depending on the specific plan. The disclosure also indicates that shares were issued or transferred to both employees and at least one director of the company.

The filing confirms that all required authorizations, regulatory requirements, and necessary filings have been completed in accordance with applicable listing rules and laws. No share buybacks, redemptions, or on-market sales of treasury shares were reported. The final aggregate number of issued shares, inclusive of treasury shares, stands at 733,500,048.